Sign up for email alert when new content gets added: Sign up
Ali Choukair
United Arab Emirates
Posters & Accepted Abstracts: J Hepato Gastroenterol
Introduction: Helicobacter pylori infection is a worldwide problem with increasing burden on the health sector due to its increasing rate of resistance. The conventional triple therapy is becoming obsolete with a high failure rate of eradication, necessitating the need for better alternatives or regimens. Methods: Ninety-two patients with dyspepsia symptoms and positive 13C-urea breath test were randomly assigned in to two groups. The first group (control group) was treated for 14 days using standard triple therapy (TT) protocol: esomeprazole (40 mg twice daily), amoxicillin (1 g twice daily) and clarithromycin (500 mg twice daily). On the other hand, the second group were prescribed a 10-day course of modified bismuth quadruple therapy (MBQT) fortified with zinc carnosine: TT in addition to bismuth subcitrate (240 mg twice daily) and zinc carnosine (75 mg twice daily). A repeated 13C-urea breath test was done 4 weeks after the completion of the eradication therapy. Results: There were no demographic differences between the two groups. The eradication rate was 93.5% (43/46) in the MBQT group compared to 69.6% (32/46) in the TT group (P = 0.003). Besides dizziness, which was recorded in MBQT group, there were no significant differences in side effects between the two groups. Conclusion: 10 days of modified bismuth quadruple therapy fortified with zinc carnosine is superior to 14 days of conventional triple therapy in eradicating Helicobacter pylori infection, with no additional significant adverse events.
